Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

China Biologic Products Inc (NASDAQ:CBPO)

During the Trading Day
94.84 -5.37 / -5.36%
As of 3:59pm ET
Day’s Change
During After-Hours   Switch to standard view »
96.17 +1.33 / +1.41%
Volume: 600.00
Health Technology

Company Description

China Biologic Products, Inc. is the non-state-owned plasma-based biopharmaceutical company approved by the Chinese government. Through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products and Guiyang Dalin Biologic Technologies, and its equity investment in Xi'an Huitian Blood Products, the firm is a fully integrated provider of plasma-based biopharmaceuticals, with capabilities spanning from plasma collection to and research and development, to product manufacturing and commercialization. The firm's key products, human albumin and immunoglobin, are often used to treat life-threatening conditions, such as low albumin, hemophilia and other blood diseases. The firm has marketed plasma-based products and a pipeline of new products to drive future growth in the large Chinese plasma market. The company was founded on December 20, 1989 and is headquartered in Shandong Province, China.

Contact Information

China Biologic Products, Inc.
18/F, Jialong International Tower
Beijing Beijing 100125
Investor Relations:



Individual stakeholders90.30%
Other institutional23.91%
Mutual fund holders11.23%

Top Executives

Xiao Ying GaoChairman, President & Chief Executive Officer
Ming YangChief Financial Officer
Gang YangVice President
Bob ZhouDirector-Marketing Department
Yin MingInvestor Relations Contact